Revive Therapeutics (XCNQ:RVV) ROCE % : -30.49% (As of Dec. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Revive Therapeutics ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Revive Therapeutics's annualized ROCE % for the quarter that ended in Dec. 2023 was -30.49%.

Revive Therapeutics ROCE % Historical Data

The historical data trend for Revive Therapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Revive Therapeutics ROCE % Chart

Revive Therapeutics Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

ROCE %

Get a 7-Day Free Trial

-150.84

-119.64

-108.04

-84.28

-52.94

Revive Therapeutics Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															-54.40	-57.48	-	-14.44	-30.49

Revive Therapeutics ROCE % Calculation

Revive Therapeutics's annualized ROCE % for the fiscal year that ended in Jun. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Jun. 2023 )		(A: Jun. 2022 )		(A: Jun. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Jun. 2023 )		(A: Jun. 2022 )		(A: Jun. 2023 )
	=	-6.277	/	( ( (17.065 - 4.166)	+	(14.252 - 3.436) )	/ 2 )
	=	-6.277	/	( (12.899	+	10.816)	/ 2 )
	=	-6.277	/	11.8575
	=	-52.94 %

Revive Therapeutics's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	-3.06	/	( ( (13.78 - 3.379)	+	(12.877 - 3.208) )	/ 2 )
	=	-3.06	/	( ( 10.401	+	9.669 )	/ 2 )
	=	-3.06	/	10.035
	=	-30.49 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Revive Therapeutics (XCNQ:RVV) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Revive Therapeutics ROCE % Related Terms

Thank you for viewing the detailed overview of Revive Therapeutics's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Revive Therapeutics (XCNQ:RVV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Revive Therapeutics Ltd (XCNQ:RVV) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

RVVTF:USA 31R:Germany

Address

82 Richmond Street East, Toronto, ON, CAN, M5C 1P1

Website

https://www.revivethera.com

Revive Therapeutics Ltd is focused on the research, development, and commercialization of novel psychedelic and cannabinoid-based life sciences products and drug repurposing for infectious diseases. The firm's technology is being developed to fill the medical needs for diseases and disorders such as pain, inflammation, and wound care.

Executives

Michael Frank

Director, Senior Officer

Revive Therapeutics (XCNQ:RVV) Headlines

No Headlines